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Abstract
De novo therapeutic design is challenged by a vast chemical repertoire and
multiple constraints such as high broad-spectrum potency and low toxicity. We
propose CLaSS (Controlled Latent attribute Space Sampling) a novel and ef-
ficient computational method for attribute-controlled generation of molecules,
which leverages guidance from classifiers trained on an informative latent
space of molecules modeled using a deep generative autoencoder. We fur-
ther screen the generated molecules by using a set of deep learning classi-
fiers in conjunction with novel physicochemical features derived from high-
throughput molecular simulations. The proposed approach is employed for
designing non-toxic antimicrobial peptides (AMPs) with strong broad-spectrum
potency, which are emerging drug candidates for tackling antibiotic resistance.
Synthesis and wet lab testing of only twenty designed sequences identified two
novel and minimalist AMPs with high potency against diverse Gram-positive
and Gram-negative pathogens, including the hard-to-treat multidrug-resistant
K. pneumoniae, as well as low in vitro and in vivo toxicity. The proposed ap-
proach thus presents a viable path for faster discovery of potent and selective
broad-spectrum antimicrobials with a higher success rate than state-of-the-art
methods.
Introduction
De novo drug design remains a cost and time-intensive process: It typically requires more
than ten years and $2-3 B USD for a new drug to reach the market, and the failure rate is nearly
90% (1). Rational methods for novel drug design, both in cerebro and in silico, heavily rely upon
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structure-activity relationship (SAR) studies. Such methods struggle with the prohibitively large
molecular space, complex structure-function relationships, and multiple competing constraints
such as activity, toxicity, synthesis cost, and stability associated with the design task. Recently,
artificial intelligence (AI) methods, in particular, statistical learning and optimization-based
approaches, have shown promise in designing novel and chemically plausible small- and macro-
molecules. In particular, deep learning-based architectures, such as neural language models
as well as deep generative neural networks, have emerged as a popular choice process (2–9).
Probabilistic autoencoders (10,11), a powerful class of deep generative models, have been used
for this design task, which learn a bidirectional mapping of the input molecules (and their
attributes) to a continuous latent space.
To achieve targeted generation, earlier deep neural net-based approaches have often limited
the learning to a fixed library of molecules with desired attributes, to restrict the exhaustive
search to a defined section of the chemical space. Such an approach can affect the novelty as
well as the validity of the generated molecules, as the fixed library represents a small portion
of the combinatorial molecular space (12). Alternative methods include Bayesian optimization
(BO) on a learned latent space (4), reinforcement learning (RL) (13, 14), or semi-supervised
learning (SS) (15). However, those approaches require surrogate model fitting (as in BO), op-
timal policy learning (as in RL), or minimizing attribute-specific loss objectives (as in SS),
which suffers from additional computational complexity. As a result, controlling attribute(s) of
designed molecules efficiently continues to remain a non-trivial task. In this study, we propose a
novel and efficient computational framework for targeted generation and screening of molecules
with desired properties. We demonstrate the efficiency of the proposed method on antimicro-
bial peptide (AMP) design problem. Antimicrobial peptides are emerging drug candidates for
tackling antibiotic resistance, one of the biggest threats in global health, food security, and de-
velopment. Patients at a higher risk from drug-resistant pathogens are also more vulnerable to
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illness from viral lung infections like influenza, severe acute respiratory syndrome (SARS), and
COVID-19. Drug-resistant diseases claim 700,000 lives a year globally (16), which is expected
to rise to 10 million deaths per year by 2050 based on current trend (17). Of particular con-
cern is multidrug-resistant Gram-negative bacteria (18). Antimicrobial peptides are typically
12-50 amino acids long and produced by multiple higher-order organisms to combat invading
microorganisms. Due to their exceptional structural and functional variety (19), promising ac-
tivity, and low tendency to induce (or even reduce) resistance, natural AMPs have been proposed
as promising alternatives to traditional antibiotics and as potential next-generation antimicrobial
agents (20). Most reported antimicrobials are cationic and amphiphilic in nature, and properties
thought to be crucial for insertion into and disruption of bacterial membrane (20). Although
several antimicrobial peptides are in clinical trials (20), the future design of novel AMP thera-
peutics requires minimizing the high production cost due to longer sequence length, proteolytic
degradation, poor solubility, and off-target toxicity. A rational path for resolving these problems
is to design short peptides as a minimal physical model (21,22) that captures the high selectivity
of natural AMPs. That is, maximizing antimicrobial activity, while minimizing toxicity towards
the host.
To tackle these challenges, the proposed in silico design framework combines novel attribute-
controlled generative models, deep learning, and physics-driven learning. For targeted genera-
tion, we propose Conditional Latent (attribute) Space Sampling - CLaSS (Fig. 2) that leverages
guidance from attribute classifier(s) trained on the latent space of the system of interest and uses
a rejection sampling scheme for generating molecules with desired attributes.
CLaSS is fundamentally novel, fast, efficient, embarrassingly parallelizable, and easily re-
purposable in comparison to existing machine learning algorithms for targeted generation. To
encourage novelty and validity of designed sequences, we performed CLaSS on the latent space
of a deep generative autoencoder that was trained on a larger dataset consisting of all known
4
peptide sequences, instead of a limited number of known antimicrobials. Extensive analyses
showed that the resulting latent space is biologically more meaningful. As a result, the an-
timicrobial peptides generated from this informative space are more novel, diverse, valid, and
optimized.
To account for additional key requirements, such as broad-spectrum nature and low toxic-
ity, we further provide an efficient in silico screening method that uses deep learning classifiers
augmented with high-throughput physics-driven molecular simulations (Fig. 1). To our knowl-
edge, this is the first computational approach for antimicrobial design that explicitly accounts for
broad-spectrum potency and low-toxicity, and performs experimental verification of those prop-
erties. Synthesis of 20 candidate sequences (from a pool of∼ 90,000 generated sequences) that
passed the screening enabled discovering two novel and minimalist peptides with experimen-
tally validated strong antimicrobial activity against diverse pathogens, including a hard-to-treat
multidrug-resistant Gram-negative K. pneumoniae. Importantly, both sequences demonstrated
low in vitro hemolysis (HC50) and in vivo lethal (LD50) toxicity. Circular dichroism experi-
ments further revealed the amphiphilic helical topology of the two novel cationic AMPs, while
all-atom simulations show a distinct mode of lipid membrane interaction. The present strategy,
therefore, provides an efficient approach for discovering novel, broad-spectrum and low-toxic
antimicrobials with a much higher (10%) success rate and faster (48 days) pace, relative to
existing methods (<1% and 2-4 years) (23).
Results
Peptide autoencoder
For modeling the peptide latent space, we used generative models based on a deep autoen-
coder (10, 11) composed of two neural networks, an encoder and a decoder. The encoder
qφ(z|x) parameterized with φ learns to map the input x to a variational distribution, and the
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decoder pθ(x|z) parameterized with θ aims to reconstruct the input x given the latent vec-
tor z from the learned distribution, as illustrated in Fig. 2A. Variational Autoencoder (VAE),
the most popular model in this family (11), assumes latent variable z ∼ p(z) and follows a
simple prior (e.g. Gaussian) distribution. And the decoder then produces a distribution over
sequences given the continuous representation z. Thus, the generative process is specified as:
p(x) =
∫
p(z)pθ(x|z)dz where we integrate out the latent variable. However, the VAE that aims
to minimize Kullback-Leibler (KL) distance between the encoded training distribution and prior
reportedly suffers from ignoring the latent z-information during decoding (24). This issue is ad-
dressed in Wasserstein Autoencoders (WAE) (25) by minimizing the optimal transport distance
or Wasserstein distance between distributions (26). Within the VAE/WAE framework, the pep-
tide generation is formulated as a density modeling problem, i.e. estimating p(x) where x are
short variable-length strings of amino acids. The density estimation procedure has to assign a
high likelihood to known peptides. Therefore, the model generalization implies that plausible
novel peptides can be generated from regions with a high probability density under the model.
Peptide sequences are presented as text strings composed of 20 natural amino acid characters.
Only sequences with length ≤ 25 were considered for model training and generation, as short
AMPs are desired.
However, instead of learning a model only over known AMP sequences, one can learn a
model overall short peptide sequences reported in the UniProt database (27) - an extensive
database of protein/peptide sequences that may or may not have an annotation. For example,
the number of annotated AMP sequences is ∼ 9000, and peptide sequences in Uniprot is ∼
1.7M, when a sequence length up to 50 is considered. Therefore, we learn a density model of
overall known peptides sequences in this work. The fact also inspires this approach, that unsu-
pervised representation learning by pre-training on a large corpus has recently led to impressive
results for downstream tasks in text and speech (28–31), as well as in protein biology (32, 33).
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Additionally, in contrast to similar models for protein sequence generation (34), we do not re-
strict ourselves to learning the density associated with a single protein family or a specific 3D
fold. Instead, we learn a global model, overall known short peptide sequences expressed in
different organisms. This global approach should enable meaningful density modeling across
multiple families, the interpolation between them, better learning of the “grammar” of plausible
peptides, and exploration beyond known antimicrobial templates, as shown next.
The advantage of training a WAE (instead of a VAE) on peptide sequences is evident from
the reported evaluation metrics in Supplementary Information (SI) Table S1 (26). We also ob-
served high reconstruction accuracy and diversity of generated sequences, when the WAE was
trained on all peptide sequences, instead of only on AMP sequences (SI Table S1). Next, we
analyzed the information content of the peptide WAE, inspired by recent investigations in nat-
ural language processing. By using the so-called “probing” methods, it has been shown that
encoded sentences can retain much linguistic information (35). In a similar vein, we investi-
gated if the evolutionary relationships between sequences (36) are captured by their encodings
in the latent z-space, as the evolutionary information is known to specify the biological function
and fold of peptide sequences. Fig. 3A reveals a negative correlation (Pearson correlation coef-
ficient =−0.63) between evolutionary similarities and Euclidean distances in the z-space of the
WAE model, suggesting that WAE intrinsically captures the evolutionary relationship within
the peptide space. The VAE latent space fails to capture such a relation.
With the end-goal of a conditional generation of novel peptide sequences, it is crucial to
ensure that the learned encoding in the z-space retains identifiable information about functional
attributes of the original sequence. Specifically, we investigate whether the space is linearly
separable into different attributes, such that sampling from a specific region of that space yields
consistent and controlled generations. For this purpose, we trained linear classifiers for binary
(yes/no) functional attribute prediction using the z encodings of sequences (Fig. 2B). Probing
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the z-space modeled by the WAE uncovers that the space is indeed linearly separable into
different functional attributes, as evident from the test accuracy of binary logistic classifiers
presented in Fig. 3B (26). Results demonstrate a performance on par with AMP classifiers
reported in literature (37, 38) or trained in-house (Fig. 3B) that have access to the original
sequences (instead of using latent features) and involve highly non-linear (neural net-based)
models. However, on toxicity classification, a much lower accuracy was found, when compared
to similar sequence-level deep classifiers (39) (also see Fig. 3B and SI Table S2) that report
accuracy as high as 90%. These results imply that some attributes, such as toxicity, are more
challenging to predict from the learned latent peptide representation; one possible reason can
be higher class imbalance in training data (26).
We also investigated the smoothness of the latent space by analyzing the sequences gener-
ated along a linear interpolation vector in the z-space between two distant training sequences
(Fig. 3C). Evolutionary similarity, functional attributes (AMP and Toxic class probabilities),
as well as several physicochemical properties including aromaticity, charge, and hydrophobic
moment (indicating amphiphilicity of a helix) change smoothly during the interpolation. These
results are encouraging, as the WAE latent space trained on the much larger amount of unla-
beled data appears to carry significant structure in terms of functional, physicochemical, and
evolutionary Figure 3C also demonstrates that it is possible to identify sequence(s) during lin-
ear interpolation that is visibly different from both endpoint sequences, indicating the potential
of the learned latent space for novel sequence generation.
CLaSS for controlled sequence generation
For controlled generation, we aim to control a set of binary (yes/no) attributes of interest
such as antimicrobial function and/or toxicity. We propose CLaSS - Conditional Latent (at-
tribute) Space Sampling for this purpose. CLaSS leverages attribute classifiers directly trained
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on the peptide z-space, as those, can capture important attribute information (Fig. 3B). Let
us formalize that there are n different (and possibly independent) binary attributes of interest
a ∈ {0, 1}n = [a1, a2, . . . , an], each attribute is only available (labeled) for a small and possibly
disjoint subset of the dataset. Since functional annotation of peptide sequences is expensive,
current databases typically represent a small (≈ 100 − 10000) subset of the unlabeled cor-
pus. We posit that all plausible datapoints have those attributes, albeit mostly without label
annotation. Therefore, the data distribution implicitly is generated as p(x) = Ea∼p(a)[p(x|a)],
where the distribution over the (potentially huge) discrete set of attribute combinations p(a) is
integrated out, and for each attribute combination the set of possible sequences is specified as
p(x|a). The goal now is to sample conditionally p(x|at) for a specified target attribute combi-
nation at. This task was approached through CLaSS (Fig. 2C), which makes the assumption
that attribute conditional density factors as follows: p(x|at) = Ez[p(z|at)p(x|z)]. We sample
p(z|at) approximately using rejection sampling from models in the latent z-space appealing
to Bayes rule and p(at|z) modeled by the attribute classifiers (Fig. 2B-C) (26). Since CLaSS
only employs simple attribute predictor models and rejection sapling from models of z-space,
it is a simple and efficient forward-only screening method. It does not require any complex
optimization over latent space, when compared to existing methods for controlled generation,
e.g. Bayesian optimization (40), reinforcement learning (13,14), or semi-supervised generative
models (15). CLaSS is easily repurposable and embarrassingly parallelizable at the same time
and does not need defining a starting point in the latent space.
Since the Toxicity classifier trained on latent features appears weaker (Fig. 3B), antimi-
crobial function (yes/no) was used as the sole condition for controlling the sampling from the
latent peptide space. Generated antimicrobial candidates were then screened for toxicity using
the sequence-level classifier during post-generation filtering.
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Features of CLaSS-generated AMPs
To check the similarity of CLaSS-generated AMP sequences with training data, we performed
a BLAST sequence similarity (or homology) search. We analyzed the Expect value (E-value)
for the matches with the highest alignment score. E-value indicates statistical (aka. biologi-
cal) significance of the match between the query and sequences from a database of a particu-
lar size. Larger E-value indicates a higher chance that the similarity between the hit and the
query is merely a coincidence, i.e. the query is not homologous or related to the hit. Typically
E-values≤ 0.001 when querying Uniprot nr database of size∼ 220 M are used to infer homol-
ogy (41). Since our training database is ∼ 1000 times smaller than Uniprot, an E-value of ≤
10−6 can be used for indicating homology. As shown in SI Table S3, about 14% of generated
sequences show an E-value of ≥ 10, and another 36% have an E-value > 1, when consid-
ering the match with the highest alignment score, indicating insignificant similarity between
generated and training sequences. If only the alignments with score > 20 are considered, the
average E-value is found to be > 2, further implying the non-homologous nature of generated
sequences. Similar criteria have also been used for detecting novelty of designed short antimi-
crobials (42). CLaSS-generated AMPs are also more diverse, as the unique (i.e. found only
once in an ensemble of sequences) k-mers (k = 3-6) are more abundant compared to training
sequences (SI Figure S1). These results highlight the ability of the present approach to generate
minimalist AMP sequences that are, on average, highly novel with respect to training data, as
well as diverse among themselves.
Distributions of key molecular features implicated in antimicrobial nature, such as amino
acid composition, charge, hydrophobicity (H), and hydrophobic moment (µH), were compared
between the training and generated AMPs, as illustrated in Fig. 4A-D. Additional features are
reported in SI Figure S1. CLaSS-generated AMP sequences show distinct character: Specifi-
cally, those are richer in R, L, S, Q, and C, whereas A, G, D, H, N, and W content is reduced, in
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comparison to training antimicrobial sequences (Fig. 4A). We also present the most abundant
k-mers (k=3, 4) in SI Figure S1, suggesting that the most frequent 3 and 4-mers are K and L-
rich in both generated and training AMPs, the frequency being higher in generated sequences.
Generated AMPs are characterized by global net positive charge and aromaticity somewhere
in between unlabeled and AMP-labeled training sequences, while the hydrophobic moment is
comparable to that of known AMPs (Fig. 4B-D and SI Figure S1). These trends imply that the
generated antimicrobials are still cationic and can form a putative amphiphilic α-helix, similar
to the majority of known antimicrobials. Interestingly, they also exhibit a moderately higher
hydrophobic ratio and an aliphatic index compared to training sequences (SI Figure S1). These
observations highlight the distinct physicochemical nature of the CLaSS-generated AMP se-
quences, as a result of the semi-supervised nature of our learning paradigm, that might help
in their therapeutic application. For example, lower aromaticity and higher aliphatic index are
known to induce better oxidation susceptibility and higher heat stability in short peptides (43),
while lower hydrophobicity is associated with reduced toxicity (44).
In silico post-generation screening
To screen the ∼90,000 CLaSS-generated AMP sequences, we first used an independent set of
binary (yes/no) sequence-level deep neural net-based classifiers that screens for antimicrobial
function, broad-spectrum efficacy, presence of secondary structure, as well as toxicity (See
Figs. 1 and 3 as well as SI Table S2). 163 candidates passed this screening, which were then
subjected to coarse-grained Molecular Dynamics (CGMD) simulations of peptide-membrane
interactions. The computational efficiency of these simulations makes them an attractive choice
for high-throughput and physically-inspired filtering of peptide sequences.
Since there exists no standardized protocol for screening antimicrobial candidates using
molecular simulations, we performed a set of control simulations of known sequences with or
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without antimicrobial activity. From those control runs, we found for the first time that the
variance of the number of contacts between positive residues and membrane lipids is predictive
of antimicrobial activity (Fig. 5): Specifically, the contact variance differentiates between high
potency AMPs and non-antimicrobial sequences with a sensitivity of 88% and specificity of
63% (26). Physically, this feature can be interpreted as measuring the robust binding tendency
of a peptide sequence to the model membrane. Therefore, we used the contact variance cutoff
of 2 for further filtering of the 163 generated AMPs that passed the classifier screening.
Wet lab characterization
A final set of 20 CLaSS-generated AMP sequences that passed the contact variance-based
screening mentioned above, along with their simulated and physico-chemical characteristics,
are reported in SI Tables S4 and S5. Those sequences were tested in the wet lab for antimi-
crobial activity, as measured using minimum inhibitory concentration (MIC, lower the bet-
ter) against Gram-positive S. aureus and Gram-negative E. coli (SI Table S6). 11 generated
non-AMP sequences were also screened for antimicrobial activity (SI Table S7). None of the
designed non-AMP sequences showed MIC values that are low enough to be considered as
antimicrobials, implying that our approach is not prone to false-negative predictions.
Among the 20 AI-designed AMP candidates, two sequences, YLRLIRYMAKMI-CONH2
(YI12, 12 amino acids) and FPLTWLKWWKWKK-CONH2 (FK13, 13 amino acids), were iden-
tified to be the best with the lowest MIC values (Fig. 6A and SI Table S6). Both peptides
are positively charged and have a nonzero hydrophobic moment (SI Table S5), indicating their
cationic and amphiphilic nature in line with known antimicrobials. These peptides were further
evaluated against the more difficult-to-treat Gram-negative P. aeruginosa, A. baummannii, as
well as a multi-drug resistant Gram-negative K. pnuemoniae. As listed in Fig. 6, both YI12 and
FK13 showed potent broad-spectrum antimicrobial activity with comparable MIC values.
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We further performed in vitro and in vivo testing for toxicity. Based on activity measure
at 50% hemolysis (HC50) and lethal dose (LD50) toxicity values (Fig. 6A and Fig. S2), both
peptides appear biocompatible (as the HC50 and LD50 values are much higher than MIC val-
ues), FK13 being more biocompatible than YI12. More importantly, the LD50 values of both
peptides compare favorably with that of polymyxin B (20.5 mg/kg) (45), which is a clinically
used antimicrobial drug for treatment of antibiotic-resistant Gram-negative bacterial infection.
Novelty of YI12 and FK13
To investigate the novelty of YI12 and FK13 with respect to training sequences, we analyzed
the sequence similarity metrics returned by the BLAST homology search in detail (Fig. 6B
and SI Figure S2), in line with earlier works (42, 46). Similarity metrics include alignment
score, E-value, percentage of alignment coverage, percentage of identity, percentage of positive
matches or similarity, and percentage of alignment gap (indicating the presence of additional
amino acids). BLAST searching with an E-value threshold of 10 against the training database
did not reveal any match for YI12, suggesting that there exists no statistically significant match
of YI12. Therefore, we further searched for related sequences of YI12 in the much larger
Uniprot database consisting of ∼ 223.5 M non-redundant sequences, only a fraction of which
was included in our model training. The closest match to YI12 shows an E-value of 2.9 with
75% identity, 83% similarity, a gap of 1 at a query coverage of 92%, which is an 11 residue
segment from the bacterial EAL domain-containing protein (Fig. 6B). This result suggests that
YI12 is significantly high in novelty, even when all protein sequences in Uniprot are considered.
We also performed a BLAST search of YI12 against the PATSEQ database that contains∼ 65.5
M patented peptides and still received a minimum E-value of 1.66. The sequence nearest to
YI12 from PATSEQ is an eight amino acid long segment from a 79 amino acid long human
protein, which has with 87.5% similarity and only 66.7% coverage, further confirming YI12’s
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high novelty.
FK13 shows less than 75% identity, a gap in the alignment, and 85% query coverage to
its closest match in the training database, implying FK13 is also novel (Fig. 6B). YI12 is
more novel than FK13, though. The closest match of FK13 in the training database is a syn-
thetic variant of a 13 amino acid long bactericidal domain (PuroA: FPVTWRWWKWWKG)
of Puroindoline-A protein from wheat endosperm. The antimicrobial and hemolysis activities
of FK13 are similar to those reported for PuroA (47, 48). Nevertheless, FK13 is significantly
different from PuroA; FK13 is K-rich and low in W-content, resulting in lower Grand Average
of Hydropathy (GRAVY) score (−0.854 vs. −0.962), higher aliphatic index (60.0 vs. 22.3), and
lower instability index (15.45 vs. 58.30), all together indicative of higher peptide stability. In
fact, lower W-content was found beneficial for stabilizing of FK13 during wet-lab experiments,
since Tryptophan (W) is susceptible to oxidation in air. Lower W-content has also been im-
plicated in improving in vivo peptide stability (49). Taken together, these results illustrate that
CLaSS on latent peptide space modeled by the WAE is able to generate novel and optimal an-
timicrobial sequences by efficiently learning the complicated sequence-function relationship in
peptides and exploiting that knowledge for controlled exploration. When combined with subse-
quent in silico screening, novel and optimal lead candidates with experimentally confirmed high
broad-spectrum efficacy and selectivity are identified at a success rate of 10%. The whole cycle
(from database curation to wet lab confirmation) took 48 days in total and a single iteration (Fig.
1).
Structural and mechanistic analyses of YI12 and FK13
Peptides were further experimentally characterized using CD spectroscopy (26). Both YI12
and FK13 showed random coil-like structure in water, but formed α-helix in 20% SDS buffer
(Fig. S2), consistent with structure classifier predictions (26). From CD spectra, α-helicity of
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YI12 appears stronger than that of FK13, in line with its stronger hydrophobic moment (SI Table
S5). In summary, physicochemical analyses and CD spectroscopy together suggest that cationic
nature and amphiphilic helical topology are the underlying factors inducing antimicrobial nature
in YI12 and FK13.
We also performed all-atom explicit water simulations (26) of these two sequences in the
presence of a lipid membrane starting from an α-helical structure, as seen in CD experiments
(Fig. S2). Different membrane binding mechanisms were observed for the two sequences, as
illustrated in Fig. 6. YI12 embeds into the membrane by using positively charged N-terminal
Arginine (R) residues. While FK13 embeds either with N-terminal Phenylalanine (F) or with
C-terminal Tryptophan (W) and Lysine (K). These results provide mechanistic insights into
different modes of action adopted by YI12 and FK13 during the early stages of membrane
interaction.
Discussion and Conclusions
Learning implicit interaction rule(s) of complex molecular systems is a major goal of artifi-
cial intelligence (AI) research. This direction is critical for designing new molecules/materials
with specific structural and/or functional requirements, one of the most anticipated and highly
needed applications. Antimicrobial peptides considered here represent an archetypal system for
molecular discovery problems. They exhibit a near-infinite and mostly unexplored chemical
repertoire, a well-defined chemical palette (natural amino acids), as well as potentially conflict-
ing or opposing design objectives, and is of high importance due to the global increase in antibi-
otic resistance and a depleted antibiotic discovery pipeline. Recent work has shown that deep
learning can be used to help screen libraries of existing chemicals for antibiotic properties (50).
A number of recent studies have also used AI methods for de novo design of antimicrobial
peptides and provided experimental validation (9, 12, 51–54). However, to our knowledge, the
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present work provides for the first time a fully automated computational framework that com-
bines novel controllable generative modeling, deep learning, and physics-driven learning for
designing broad-spectrum potent and selective AMP sequences and experimentally validating
them for the set of desired attributes. Wet lab results confirmed the efficiency of the proposed
approach for designing novel and optimized sequences with a very modest number of candidate
compounds synthesized and tested. The present design approach in this proof-of-concept study
yielded a 10% success rate and a rapid turnaround of 48 days, as opposed to a 1% success rate
and a timeline of 2-4 years required for antimicrobial lead generation (23). The generative mod-
eling approach presented here can be tuned for not only generating novel candidates, but also
for designing novel combination therapies and antibiotic adjuvants, to further advance antibiotic
treatments.
Since CLaSS is a generic approach, it is suitable for a variety of controlled generation tasks
and can handle multiple controls simultaneously. The method is simple to implement, fast,
efficient, and scalable, as it does not require any optimization over the latent space. CLaSS has
additional advantages regarding repurposability, as adding a new constraint requires a simple
predictor training. Therefore, future directions of this work will explore the effect of additional
relevant constraints, such as the induced resistance and fine-grained strain-specificity, on the
designed AMPs using the approach presented here. Finally, the AI models will be further
optimized in an iterative manner by using the feedback from simulations and/or experiments in
an active learning framework.
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Online Methods
Generative Autoencoders
To learn meaningful continuous latent representations from sequences without supervision sig-
nal, the Variational Autoencoder (VAE) (11) family has emerged as a principled and successful
method. The data distribution p(x) over samples x is represented as the marginal of a joint
distribution p(x, z) that factors out as p(z)pθ(x|z). The prior p(z) is a simple smooth distri-
bution, while pθ(x|z) is the decoder that maps a point in latent z-space to a distribution in x
data space. The exact inference of the hidden variable z for a given input x would require
integration over the full latent space: p(z|x) = p(z)pθ(x|z)∫
dzp(z)pθ(x|z) . To avoid this computational bur-
den, the inference is approximated through an inference neural network or encoder qφ(z|x).
Our implementation follows (55), where both encoder and decoder are single-layer LSTM re-
current neural networks (56), and the encoder specifies a diagonal Gaussian distribution, i.e.
qφ(z|x) = N(z;µ(x),Σ(x)) (Fig. 2).
The basis for auto-encoder training is optimization of an objective consisting of the sum of
a reconstruction loss and a regularization constraint loss term: L(θ, φ) = Lrec(θ, φ) + Lc(φ).
In the standard VAE objective (11), reconstruction loss Lrec(θ, φ) is based on the negative log
likelihood of the training sample, and the constraint Lc(φ) uses DKL, the Kullback-Leibler
divergence:
LVAE(θ, φ) = Eqφ(z|x)[log pθ(x|z)]−DKL(qφ(z|x)||p(z))
for a single sample. This exact objective is derived from a lower bound on the data likelihood;
hence this objective is called the ELBO (Evidence Lower Bound). With the standard VAE,
we observed the same posterior collapse as detailed for natural language in the literature (24),
meaning q(z|x) ≈ p(z) such that no meaningful information is encoded in z space. Further ex-
tensions include β-VAE that adds a multiplier “weight” hyperparameter β on the regularization
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term, and δ-VAE that encourages the DKL term to be close to a nonzero δ, etc., to tackle the
issue of posterior collapse. However, finding the right setting that serves as a workaround for
the posterior collapse is tricky within these VAE variants.
Therefore, many variations within the VAE family have been recently proposed, such as
Wasserstein Autoencoder (WAE) (25, 57) and Adversarial Autoencoder (AAE) (58).
WAE factors an optimal transport plan through the encoder-decoder pair, on the constraint
that marginal posterior qφ(z) = Ex∼p(x)qφ(z|x) equals a prior distribution, i.e. qφ(z) = p(z).
This is relaxed to an objective similar to LVAE above. However, in the WAE objective (25),
instead of each individual qφ(z|x), the marginal posterior qφ(z) = Ex[qφ(z|x)] is constrained
to be close to the prior p(z). We enforce the constraint by penalizing maximum mean dis-
crepancy (59) with random features approximation of the radial basis function (60): Lc(φ) =
MMD(qφ(z), p(z)). The total objective for WAE is L = Lrec + Lc where we use the recon-
struction loss Lrec = −Eqφ(z|x)[log pθ(x|z)]. In WAE training with maximum mean discrepancy
(MMD) or with a discriminator, we found a benefit of regularizing the encoder variance as in
the literature (57, 61). For MMD, we used a random features approximation of the Gaussian
kernel (60).
Details of autoencoder architecture and training, as well as an experimental comparison
between different auto-encoder variations tested in this study, can be found in Supplementary
Material sections C.1.1, C.1.2 and C.1.4.
CLaSS - Conditional Latent (Attribute) Space Sampling
We propose Conditional Latent (attribute) Space Sampling, CLaSS, a simple but elegant method
to sample from the targeted region of the latent space from an auto-encoder, which was trained
in an unsupervised manner (Fig. 2).
Density Modeling in Latent Space We assume a latent variable model (e.g., Autoencoder)
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that has been trained in an unsupervised manner to meet the evaluation criteria outlined in (26).
All training data xj are then encoded in latent space: zj,k ∼ qφ(z|xj). These zj,k are used to fit
an explicit density model Qξ(z) to approximate marginal posterior qφ(z), and a classifier model
qξ(ai|z) forr attribute ai to approximate the probability p(ai|x). The motivation for fitting a
Qξ(z) is in order to sample fromQξ rather than p(z), since at the end of training the discrepancy
between qφ(z) and p(z) can be significant.
Although any explicit density estimator could be used for Qξ(z), here we consider Gaussian
mixture density models and evaluate negative log-likelihood on a held-out set to determine the
optimal complexity. We find 100 components and untied diagonal covariance matrices to be
optimal, giving a held-out log likelihood of 105.1. To fit Qξ, we use K=10 random samples
from the encoding distribution of the training data, zj,k ∼ qφ(z|xj) = N (µ(xj), σ(xj)), with
k = 1 . . . K.
Independent simple linear attribute classifiers qξ(ai|z) are then fitted per attribute. For each
attribute ai, the procedure consists of: (1) collecting dataset with all labeled samples for this
attribute (xj, ai), (2) encoding the labeled data as before, zj,k ∼ qφ(z|xj), (3) fitting ξ, the
parameters of logistic regression classifier qξ(ai|z) with inverse regularization strength C = 1.0
and 300 lbfgs iterations.
Rejection Sampling for Attribute-Conditioned Generation Recall our aim of sampling
novel sequences x ∼ p(x|a), for a desired attribute combination a = [a1, . . . , an]. We are now
able to approach this task through conditional sampling in latent space:
p(x|a) = Ez[p(z|a)p(x|z)] (1)
≈ Ez[pˆξ(z|a)pθ(x|z)] (2)
Where pˆξ(z|a) will not be approximated explicitly, rather we will use rejection sampling using
the models Qξ(z) and qξ(ai|z) to approximate samples from p(z|a).
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To approach this, we first use Bayes’ rule and the conditional independence of the attributes
ai conditioned on z, since we assume the latent variable captures all information to model the
attributes: ai ⊥ aj|z (i.e. two attributes ai and aj are independent when conditioned on z)
p(z|a) = p(a|z)qφ(z)
p(a)
(3)
=
qφ(z)
∏
i p(ai|z)
p(a)
(4)
This approximation is introduced to pˆξ(z|a), using the models Qξ and qξ above:
pˆξ(z|a) = Qξ(z)
∏
i qξ(ai|z)
qξ(a)
(5)
The denominator qξ(a) in Eq. (5) could be estimated by approximating the expectation
qξ(a) = EQξ(z)qξ(a|z) ≈ 1N
∑N
zj∼Qξ(z) qξ(a|z). However, the denominator is not needed a
priori in our rejection sampling scheme, in contrast, qξ(a) will naturally appear as the rejection
rate of samples from the proposal distribution (see below).
For rejection sampling distribution with pdf f(z), we need a proposal distribution g(z) and
a constant M , such that f(z) ≤ Mg(z) for all z, i.e. Mg(z) envelopes f(z). We draw samples
from g(z) and accept the sample with probability f(z)
Mg(z)
≤ 1.
In the above, to sample from Eq. (5), we consider a to be constant. We perform re-
jection sampling through the proposal distribution: g(z) = Qξ(z) that can be directly sam-
pled. Now set M = 1/qξ(a) so Mg(z) = Qξ(z)/qξ(a), while our pdf to sample from is
f(z) = Qξ(z)
∏
i qξ(ai|z)/qξ(a). Therefore, we accept the sample from Qξ(z) with probability
f(z)
Mg(z)
=
∏
i
qξ(ai|z) ≤ 1
The inequality trivially follows from the product of normalized probabilities. The acceptance
rate is 1/M = qξ(a). Intuitively, the acceptance probability is equal to the product of the
classifier’s scores, while sampling from explicit density Qξ(z). In order to accept any samples,
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we need a region in z space to exist where Qξ(z) > 0 and the classifiers assign a nonzero
probability to all desired attributes, i.e. the combination of attributes has to be realizable in
z-space.
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Figure 1: Overview and timeline of the proposed AI-driven approach for accelerated antimicro-
bial design.
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Figure 2: (A) Training a generative Autoencoder (AE) model on peptide sequences (AE Train-
ing in Fig. 1), (B) Mapping sparse peptide attributes to the model’s latent z-space (AE Training
in Fig. 1), and (C) Sampling from the z-space using our CLaSS method (Generation in Fig. 1).
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Figure 3: (A) Relation between evolutionary similarity and Euclidean distance in latent z-space,
when sequences were modeled using WAE (VAE in Inset). Darker points indicate similarity
with itself (i.e. the same exact sequence). (B) Class prediction accuracy (%) of attribute clas-
sifiers on test data. Classifiers were trained either using WAE z-space encodings (z-) or on
sequences (sequence-level). (C) Decoded sequences and their attributes during a linear inter-
polation between two distant sequences in the WAE latent space. Attributes include (1) physic-
ochemical properties, (2) evolutionary similarity (evo start, evo end) from endpoint se-
quences, and (3) AMP (z amp) and Toxic (z tox) class probabilities from z-classifiers. Values
in orange and blue are in the upper and lower quartile, respectively. Black rectangle indicates
sequences with low attribute similarity to endpoint sequences. As an example of further analy-
sis, we show the relation of AMP class probability and instability index for all candidates in the
interpolation and a ball-stick rendering of a selected sequence in the path.
24
A C D E F G H I K L M N P Q R S T V W Y
Global Charge
Fr
ac
tio
n
G
lo
ba
lH
yd
ro
ph
ob
ic
ity
G
lo
ba
lH
yd
ro
ph
ob
ic
M
om
en
t
Amino Acids:
Fr
ac
tio
n
A
B C D
Figure 4: Comparison of amino acid composition (A), global hydrophobicity (B), hydrophobic
moment (C), and charge distribution (D) of CLaSS-generated AMPs with training sequences.
Mean and standard deviation were estimated on three different sets, each consisting 3000 ran-
domly chosen samples. Generated AMP: orange; training AMP: blue; training unlabeled: gray.
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Figure 5: (A) Snapshot from a coarse-grained molecular dynamics simulation of an AMP (in
orange) binding with a lipid bilayer (gray). (B) Confusion matrix of the simulation-based clas-
sifier that uses peptide-membrane contact variance as feature for detecting AMP sequences.
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Sequence
S. aureus
(μg/ml)
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(μg/ml)
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(μg/ml)
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baumannii
(μg/ml)
MDR K.
pneumoniae
(μg/ml)
HC50
(μg/ml)
LD50
(mg/kg)
YLRLIRYMAKMI-CONH2 (YI12) 7.8 31.25 125 15.6 31.25 125 182
FPLTWLKWWKWKK-CONH2 (FK13) 15.6 31.25 62.5 31.25 15.6 500 158
Broad-spectrum antimicrobial activity and toxicity of two best CLaSS-designed peptidesA
B
C
Blast search results of YI12 against 223.5M Uniprot sequences
>WP_027115309.1 EAL domain-containing protein
[Lachnospiraceae bacterium P6B14]
Length=643
Score = 33.3 bits (71), Expect = 2.9 , Coverage= 11/12 (91.6%)
Identities = 9/12 (75%), Positives = 10/12 (83%), Gaps = 1/12 (8%)
Query 1 YLRLIRYM-AKM 11
a
YLR+IRYM KM
a
Sbjct 353 YLRMIRYMESKM 364
Blast search results of FK13 against 0.18 M training sequences
>Synthetic variant of PIN-A segment of Puroindoline-A
Length=13
Score = 33.3 bits (71), Expect = 1e-06, Coverage= 11/13 (84.6%)
Identities = 8/11 (73%), Positives = 8/11 (73%), Gaps = 1/11 (9%)
Query 1 FPLTWLKWWKW 11
FPLTW WWKW
Sbjct 1 FPLTW-RWWKW 10
Figure 6: (A) MIC values against diverse strains, including one that is multidrug-resistant
(MDR), hemolytic activity measured at 50% hemolysis (HC50) using rat red blood cells, and
lethal dose toxicity (LD50) values for Balb/C mice for YI12 and FK13, two best CLaSS-
designed AMPs. (B) BLAST search results of YI12 and FK13. (C) Snapshot from all-atom
simulation of YI12 and FK13. Selected residues that interact with the membrane are high-
lighted.
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A Supplementary Text
A.1 Rational AMP Design Methods
Rational AMP design methods (62,63), both in cerebro and in silico, heavily rely upon structure-
activity relationship (SAR) studies (42,64–66). However, incomplete understanding of complex
sequence-function relationship remains as one major bottleneck for efficient lead generation or
optimization, even when restricted to a fixed library of sequences. Recent methods for AMP
discovery have therefore relied heavily on statistical learning and optimization, which includes
linguistic approaches (51), neural language models (9), evolutionary optimization (12, 52, 53),
or sub-graph matching (54). These approaches typically learn only from peptide sequences re-
ported with antimicrobial activity, which can limit the exploratory capability of the statistical
model. In addition, none of these methods explicitly account for broad-spectrum potency and
low toxicity requirements for designing therapeutic AMPs, which is different from the present
work.
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A.2 Conditional Generation with Autoencoders
Since the peptide sequences are represented as text strings here, we will be limiting our discus-
sion to literature around text generation with constraints. Controlled text sequence generation
is non-trivial, as the discrete and non-differentiable nature of text samples does not allow the
use of a global discriminator, which is commonly used in image generation tasks to guide gen-
eration. To tackle this issue of non-differentiability, policy learning has been suggested, which
suffers from high variance during training (13,67). Therefore, specialized distributions, such as
the Gumbel-softmax (68, 69), a concrete distribution (70), or a soft-argmax function (71), have
been proposed to approximate the gradient of the model from discrete samples.
Alternatively, in a semi-supervised model setting, the minimization of element-wise recon-
struction error has been employed (72), which tends to lose the holistic view of a full sen-
tence. Hu et al. (73) proposed a VAE variant that allows both controllable generation and
semi-supervised learning. The working principle needs labels to be present during training and
encourages latent space to represent them, so the addition of new attributes will require re-
training the latent variable model itself. The framework relies on a set of new discrete binary
variables in latent space to control the attributes, an ad-hoc wake-sleep procedure. It requires
learning the right balance between multiple competing and tightly interacting loss objectives,
which is tricky.
Engel et al. (74) propose a conditional generation framework without retraining the model,
similar in concept to ours, by modeling in latent space post-hoc. Their approach does not need
an explicit density model in z-space, rather relies on adversarial training of generator and at-
tribute discriminator and focuses modifying sample reconstructions rather than generating novel
samples. Recent Plug and Play Language Model (PPLM) for controllable language generation
combines a pre-trained language model (LM) with one or more simple attribute classifiers that
guide text generation without any further training of the LM (75).
38
A.3 Conditional Generation for Molecule Design
Following the work of Gmez-Bombarelli et al. (40), Bayesian Optimization (BO) in the learned
latent space has been employed for molecular optimization for properties such as drug likeli-
ness (QED) or penalized logP. The standard BO routine consists of two key steps: (i) estimating
the black-box function from data through a probabilistic surrogate model; usually a Gaussian
process (GP), referred to as the response surface; (ii) maximizing an acquisition function that
computes a score that trades off exploration and exploitation according to uncertainty and opti-
mality of the response surface. As the dimensionality of the input latent space increases, these
two steps become challenging. In most cases, such a method is restricted to local optimization
using training data points as starting points, as optimizers are likely to follow gradients into
regions of the latent space that the model has not been exposed to during training. Reinforce-
ment learning (RL) based methods provide an alternative approach for molecular optimiza-
tion (14, 76–78), in which RL policies are learned by incorporating the desired attribute as part
of the reward. However, a large number of evaluations are typically needed for both BO and
RL-based optimizations while trading off exploration and exploitation (79). Semi-supervised
learning has also been used for conditional generation of molecules (15, 80–82), which needs
labels to be available during the generative model training.
CLaSS is fundamentally different from these existing approaches, as it does not need ex-
pensive optimization over latent space, policy learning, or minimization of complex loss objec-
tives - and therefore does not suffer from cumbersome computational complexity. Furthermore,
CLaSS is not limited to local optimization around an initial starting point. Adding a new con-
straint in CLaSS is relatively simple, as it only requires a simple predictor training; therefore,
CLaSS is easily repurposable. CLaSS is embarrassingly parallelizable as well.
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B Dataset
B.1 A Dataset for Semi-Supervised Training of AMP Generative Model
We compiled a new two-part (unlabeled and labeled) dataset for learning a meaningful rep-
resentation of the peptide space and conditionally generating safe antimicrobial peptides from
that space using the proposed CLaSS method. We consider discriminating for several functional
attributes as well as for presence of structure in peptides. Only linear and monomeric sequences
with no terminal modifications and length up to 50 amino acids were considered in curating this
dataset. As a further pre-processing step, the sequences with non-natural amino acids (B, J, O,
U, X, and Z) and the ones with lower case letters were eliminated.
Unlabeled Sequences: The unlabeled data is from Uniprot-SwissProt and Uniprot-Trembl
database (27) and contains just over 1.7 M sequences, when considering sequences with length
up to 50 amino acid.
Labeled Sequences: Our labeled dataset comprises sequences with different attributes cu-
rated from a number of publicly available databases (39, 83–86). Below we provide details of
the labeled dataset:
• Antimicrobial (8683 AMP, 6536 non-AMP);
• Toxic (3149 Toxic, 16280 non-Toxic);
• Broad-spectrum (1302 Positive, 1238 Negative);
• Structured (1170 Positive, 2136 Negative);
• Hormone (569 Positive);
• Antihypertensive (1659 Positive);
• Anticancer (504 Positive).
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B.1.1 Details of Labeled Datasets
Sequences with AMP/non-AMP Annotation. AMP labeled dataset comprises sequences from
two major AMP databases: satPDB (83) and DBAASP (84), as well as a dataset used in an ear-
lier AMP classification study named as AMPEP (86). Sequences with an antimicrobial function
annotation in satPDB and AMPEP or a MIC value against any target species less than 25 µg/ml
in DBAASP were considered as AMP labeled instances. The duplicates between these three
datasets were removed to generate a non-redundant AMP dataset. And, the ones with mean
activity against all target species > 100 µg/ml in DBAASP were considered negative instances
(non-AMP). Since experimentally verified non-AMP sequences are rare to find, the non-AMP
instances in AMPEP were generated from UniProt sequences after discarding sequences that
were annotated as AMP, membrane, toxic, secretory, defensive, antibiotic, anticancer, antiviral,
and antifungal and were used in this study as well.
Sequences with Toxic/nonToxic Annotation: Sequences with toxicity labels are curated
from satPDB and DBAASP databases as well as from the ToxinPred dataset (39). Sequences
with “Major Function” or “Sub Function” annotated as toxic in satPDB and sequences with
hemolytic/cytotoxic activities against all reported target species less than 200 µg/ml in DBAASP
were considered as Toxic instances. The toxic-annotated instances from ToxinPred were added
to this set after removing duplicates resulting in a total to 3149 Toxic sequences. Sequences
with hemolytic/cytotoxic activities > 250 µg/ml were considered as nonToxic. The nonToxic
instances reported in ToxinPred (sequences from SwissProt or TrEMBL that are not found in
search using keyword associated with toxins, i.e. keyword (NOT KW800 NOT KW20) or
keyword (NOT KW800 AND KW33090), were added to the nonToxic set, totaling to 16280
non-AMP sequences.
Sequences with Broad-Spectrum Annotation Antimicrobial sequences reported in the sat-
PDB or DBAASP database can have both Gram-positive and Gram-negative strains as target
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groups. We consider such sequences as broad-spectrum. Otherwise, they are treated as narrow-
spectrum. Through our filtering, we found 1302 broad-spectrum and 1238 narrow-spectrum
sequences.
Sequences with Structure/No-Structure Annotation: Secondary Structure assignment
was performed for structures from satPDB using the STRIDE algorithm (87). If more than
60% of the amino acids are helix or beta-strand, we label it as structured (positive). Otherwise,
they are labeled as negative. Through this filtering, we found 1170 positive sequences and 2136
negative sequences.
Peptide Dataset for Baseline Simulations: For the control simulations, three datasets were
prepared. The first two were taken from the satpdb dataset, filtering sequences with length
smaller than 20 amino acids. The high potency dataset contains the 51 sequences with the
lowest average MIC, excluding sequences with cysteine residues. All these sequences have an
average MIC of less than 10 µg / ml. The low potency dataset contains the 41 sequences with
the highest MIC, excluding cysteine residues. All these have an average MIC over 300 µg / ml.
To create a dataset of inactive sequences, we queried UniProt using the following keywords:
NOT keyword:”Antimicrobial [KW-0929]” length:[1 TO 20] NOT keyword:”Toxin [KW-0800]”
NOT keyword:”Disulfide bond [KW-1015]” NOT annotation:(type:ptm) NOT keyword:”Lipid-
binding [KW-0446]” NOT keyword:”Membrane [KW-0472]” NOT keyword:”Cytolysis [KW-
0204]” NOT keyword:”Cell wall biogenesis/degradation [KW-0961]” NOT keyword:”Amphibian
defense peptide [KW-0878]” NOT keyword:”Secreted [KW-0964]” NOT keyword:”Defensin
[KW-0211]” NOT keyword:”Antiviral protein [KW-0930]” AND reviewed:yes. From this, we
picked 54 random sequences to act as the inactive dataset for simulation.
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C Model and Methods
C.1 Autoencoder Details
C.1.1 Autoencoder Architecture
We investigate two different types of autoencoding approaches: β-VAE (24) and WAE (25) in
this study. For each of these AEs the default architecture involves bidirectional-GRU encoder
and GRU decoder. For the encoder, we used a bi-directional GRU with hidden state size of 80.
The latent capacity was set at D = 100.
For VAE, we used KL term annealing β from 0 to 0.03 by default. We also present an
unmodified VAE with KL term annealing β from 0 to 1.0. For WAE, we found that the random
features approximation of the gaussian kernel with kernel bandwidth σ = 7 to be performing
the best. For comparison sake, we have included variations with σ values of 3 and 15 too.
The inclusion of z-space noise logvar regularization, R(logV ar), helped avoiding collapse to
a deterministic encoder. Among different regularization weights used, 1e − 3 had the most
desirable behavior on the metrics (see Section C.1.4).
C.1.2 Autoencoder Training
When training the AE model, we sub selected sequences with length ≤ the hyperparameter
max seq length. Furthermore, both AMP-labeled and unlabeled data were split into train,
held out, and test set. This reduces the available sequences for training; e.g for unlabeled set the
number of available training sequences are 93k formax seq length=25, whereas the number of
AMP-labeled sequences was 5000. The sequences with reported activities were considered as
confirmed labeled data, and those with confirmed labels were up-sampled at a 1:20 ratio. Such
upsampling of peptides with a specific attribute label will allow mitigation of possible domain
shift due to unlabeled peptides coming from a different distribution. However, the benefit of
transfer learning from unlabeled to labeled data likely outweighs the effects of domain shift.
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To obtain the optimal hyperparameter setting for autoencoder training, we adopted an auto-
mated hyperparameter optimization. Specifically, we performed a grid search in the hyperpa-
rameter space and tracked an L2 distance between the reconstructions of held-out data and train-
ing sequences, which was estimated using a weighted combination of BLEU, PPL, z-classifier
accuracy, and amino acid composition-based heuristics. The best hyperparameter configuration
obtained using this process was the following: learning rate = 0.001, number of iterations =
200000, minibatch size = 32, word dropout = 0.3. A beam search decoder was used with a
beam size of 5.
C.1.3 Autoencoder Evaluation
Evaluation of generative models is notoriously difficult (88). In the variational auto-encoder
family, two competing objective terms are minimized: reconstruction of the input and a form
of regularization in the latent space, which form a fundamental trade-off (89). Since we want
a meaningful and consistent latent space, models that do not compromise the reconstruction
quality to achieve lower constraint loss are preferred. We propose an evaluation protocol using
four metrics to judge the quality of both heldout reconstructions and prior samples (90). The
metrics are
(i) The objective terms, evaluated on heldout data: reconstruction log likelihood− log pθ(x|z)
and D(qhφ(z)|p(z)), where qhφ(z) = 1Nhld
∑
xi∼hld qφ(z|xi) is the average over heldout en-
codings.
(ii) Encoder variance log(σ2j (x
i)) averaged over heldout samples, in L2 over components j. In
order to achieve a meaningful latent space, we needed to regularize the encoder variance to
not becoming vanishingly small, i.e., for the encoder to become deterministic (61). Large
negative values indicate that the encoder is collapsed to deterministic.
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(iii) Reconstruction BLEU score on held-out samples.
(iv) Perplexity (PPL) evaluated by an external language model, for samples from prior p(z)
and heldout encoding qφ(z|x).
Note that (iii) and (iv) involve sampling the decoder (we use beam search with beam 5), which
will therefore also take into account any exposure bias (91,92). We propose to evaluate peptide
generation using the perplexity under an independently trained language model (iv), which is a
reasonable heuristic (93) if we assume the independent language model captures the distribution
p(x) well.
External Language Model We trained an external language model on both labeled and un-
labeled sequences to determine the perplexity of the generated sequences. Specifically, we used
a character-based LSTM language model (LM) with the help of LSTM and QRNN Language
Model Toolkit (94) trained on both AMP-labeled and unlabeled data. We trained our language
model with a total of 92624 sequences, with a maximum sequence length of 25. Our best model
achieves a test perplexity of 13.26.
To further validate the performance of our language model, we tested it on sequences with
randomly generated synthetic amino acids from the vocabulary of lengths ranging between 10
to 25. As expected, we found it to have a high perplexity of 27.29. Also, when evaluating it for
repeated amino acids (sequence consisting of a single token from vocabulary), of length ranging
between 10 to 25, we found the perplexity to be very low (3.48). Upon further investigation,
we observed that the training data consists of amino acids with repeated sub-sequences, which
the language model by nature, fails to penalize heavily. Due to this behavior, we can conclude
that the perplexity of a collapsed peptide model will be closer to 3.48 (as seen in the case of
β-VAE). We have summarized these observation in Table S1.
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Architecture PPL BLEU Recon Encoder variance
Reference
Repeated Sequences 3.48
Random 27.29
AMP-labeled 5.580
Labeled+Unlabeled 13.26
β-VAE (1.0) 3.820 4e-03 2.768 -2.5e-4
β-VAE (0.03) 15.34 0.475 1.075 -0.620
WAE, σ = 3, R(logV ar) = 1e− 3 13.25 0.853 0.257 -3.078
WAE, σ = 15, R(logV ar) = 1e− 3 12.98 0.909 0.224 -4.180
WAE, σ = 7, R(logV ar) = 0 12.77 0.881 0.214 -13.81
WAE, σ = 7, R(logV ar) = 1e− 2 15.16 0.665 0.685 -0.3962
WAE, σ = 7, R(logV ar) = 1e− 3 12.87 0.892 0.216 -4.141
WAE (trained on AMP-labeled) 16.12 0.510 0.354 -4.316
Table S1: Performance of various autoencoder schemes against different baselines.
C.1.4 Autoencoder Variants: Comparison
The evaluated metrics on held-out samples for different autoencoder models trained on either
labeled or full dataset are also reported in Table S1. We observed that the reconstruction of WAE
is more accurate compared to β-VAE: we achieve a reconstruction error of 0.2163 and a BLEU
score of 0.892 on a held-out set using WAE with σ of 7 and R(logV ar) of 1e-3 (values are
1.079 and 0.493 for β-VAE with β set to 0.03). The advantage of using abundant unlabeled data
compared to only the labeled ones for representation learning is evident, as the language model
perplexity (PPL, captures sequence diversity) for the WAE model trained on a full dataset is
closer to that of the test perplexity (13.26), and the BLEU score is also higher when compared
to the WAE model trained only on AMP-labeled sequences. For reference, PPL of random
peptide sequences is > 25, and for repeated sequences is 3.48. The z-classifier trained on the
latent space of the best WAE model achieved a test accuracy of 87.4, 68.9, 77.4, 98.3, 76.3%
for detecting peptides with AMP/non-AMP, toxic/non-toxic, anticancer, antihypertensive, and
hormone annotation.
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C.2 Post-Generation Screening
C.2.1 Sequence-Level Attribute Classifiers
For post-generation screening, we used four sets of monolithic classifiers that are trained di-
rectly on peptide sequences. Each of these binary sequence-level classifiers was aimed at cap-
turing one of the following four properties of peptide sequences, namely,
• AMP/Non-AMP : Is the sequence an AMP or not?
• Toxicity/Non-Toxic : Is the sequence toxic or not?
• Broad/Narrow : Does the sequence show antibacterial activity on both Gram+ and Gram-
strains or not?
• Structure/No-Structure : Does the sequence have secondary structure or not?
For each attribute, we trained a bidirectional LSTM-based classifier on the labeled dataset.
We used a hidden layer size of 100 and a dropout of 0.3. Size of dataset used as well as
accuracies are reported in the Table S2.
Attribute Data-Split Accuracy (%) Screening
Train Valid Test Majority Class Test Threshold{
AMP , Non-AMP
}
6489 811 812 68.9 88.0 7.944{
Toxic , Non-Toxic
}
8153 1019 1020 82.73 93.7 -1.573{
Broad, Narrow
}
2031 254 255 51.37 76.0 -7.323{
Structure , No-Structure
}
2644 331 331 64.65 95.1 -5.382
Table S2: Performance of classifiers based on different attributes.
Based on the distribution of the scores (classification probabilities/logits), we determined
the threshold by considering the 50th percentile (median) of the scores ( reported in the last
column of Table S2). Similarly, we selected a PPL threshold of 16.04 that is the 25th percentile
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of the PPL distribution of samples generated from the prior distribution of the best WAE model
and also closer to the perplexity of our trained language model on test data.
C.2.2 CGMD Simulations - Contact Variance as a Metric for Classifying Membrane
Binding
Given a peptide sequence as an input, PeptideBuilder (95) is used to prepare a PDB file of the
all-atom representation of the peptide. This is prepared either as an alpha helix (with dihedral
angles φ = −57, ψ = −47) or as a random coil, with φ and ψ dihedral angles taking random
values between −50◦ and 50◦.
This initial structure is then passed as in input to martinize.py (96), which coarse-
grains the system. The resulting files are passed into insane.py (97) to create the peptide
membrane system. The solvent is a 90:10 ratio of water to antifreeze particles, with the mem-
brane being a 3:1 mixture of POPC to POPG. The system is 15 nm x 15 nm x 30 nm, with the
membrane perpendicular to the longest direction. Ions are added to neutralize the system.
For the CGMD simulations, we used the Martini forcefield (98), as Martini is optimized for
predicting the interactions between proteins and membranes while being computationally effi-
cient, it is well suited for the task of a quick but physically-inspired filtering peptide sequences.
After building, the system is minimized for 50,000 steps using Gromacs 2019.1 (99, 100)
and the 2.0 version of the Martini forcefield (98). After minimization, the production run is
carried for 1 µs at a 20 fs timestep. Temperature is kept constant at 310 K using Stochastic
Velocity Rescaling (101) applied independently to the protein, lipid, and the solvent groups.
The pressure is kept constant at 1 atmosphere using a Parrinello-Rahman barostat (102, 103)
applied independently to the same groups as the thermostat.
After 1 µs of sampling, we estimated the number of peptide-membrane contacts using TCL
scripting and in-house Python scripts. The number of contacts between positive residues and
the lipid membranes is defined as the number of atoms belonging to a lipid at a distance less
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than 7.5 A˚ from a positive residue.
For the control simulations, three datasets consisting of reported high-potency AMP, low-
potency AMP, and non-AMP sequences were used that are discussed in B.1.1. We performed
a set of 130 control simulations. We found that the variance of the number of contacts (cutoff
7.5 A˚) between positive residues and Martini beads of the membrane lipids is predictive of
antimicrobial activity. Specifically, the contact variance distinguishes between high potency
and non-antimicrobial sequences with a sensitivity of 88% and specificity of 63%. To screen,
we used a cutoff value of 2 beads for the contact variance. We carried out a set of simulations
for the 163 amp-positive and 179 amp-negative generated sequences. We further restricted to
sequences that bind in less than 500 ns during the 1µs long simulation, so that the contact
variance is calculated over at least half of the total simulation time. Only sequences that formed
at least 5 contacts (averaged over the duration of the simulation) were considered.
C.3 All-Atom Simulations
We used the CHARMM36m (104) forcefield to simulate the binding of four copies of YL12
and FK13 to a model membrane. Phi and Psi angles in the initial peptide structure were set to
what was predicted using a recent deep learning model (105). A 3:1 DLPC:DLPG bilayer, with
shorter tails, was used to speed up the simulation, alongside a smaller water box (98 A˚) than
the Martini simulations, to investigate the short-term effect of peptide-membrane interactions.
A 160 ns long trajectory was run for the FK13 system. The length of the YI12 simulation was
200 ns. The number of peptide-membrane and peptide-peptide contacts (using a threshold of
7.5 A˚ and ignoring hydrogen atoms) were found to be converged in less time than the maximum
simulation length for both systems.
The bilayer is prepared using CHARMM-GUI (106), and the peptide sequence is prepared
using PeptideBuilder (95). Solvation and assembly is performed using VMD 1.9.3 (107). The
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system is simulated using NAMD 2.13 (108). Temperature is kept constant using a Langevin
thermostat and a Nose´-Hoover Langevin piston barostat The Particle-Mesh Ewald method was
used for long-range electrostatics. All simulations used a time step of 2 fs.
C.4 Peptide Sequence Analysis
Physicochemical properties like aromaticity, Eisenberg hydrophobicity, charge, charge density,
aliphatic index, hydrophobic moment, hydrophobic ratio, isoelectric point, and instability index
were estimated using the GlobalAnalysis method in modLAMP (109). Protparam tool from
Expasy (https://web.expasy.org/protparam) was used to estimate the grand average of hydro-
pathicity (GRAVY) score.
Pairwise evolutionary similarity was estimated using a global alignment method, the PAM30
matrix (36), a gap open penalty of -9, and a gap extension penalty of -1 using Pairwise2 function
of Biopython package (110). Higher positive values indicate better similarity. To check the
correspondence between evolutionary similarity and Euclidean distance in z-space, a random
set of sequence encodings were first selected, and then evolutionary similarity and z-distance
with their close latent space neighbors were estimated. Sequence similarity with respect to a
sequence database was estimated using “blastp-short” command from NCBI BLAST sequence
similarity search tool (111, 112) was used to query generated short sequences by using a word
size of 2, the PAM30 matrix (36), a gap open penalty of -9, a gap extension penalty of -1,
threshold of 16, comp based stats set to 0 and window size of 15. Alignment score (Bit score),
Expect value (E-value), percentage of alignment coverage, percentage of identity, percentage of
positive matches or similarity, percentage of alignment gap were used for analyzing sequence
novelty. The E-value is a measure of the probability of the high similarity score occurring by
chance when searching a database of a particular size. E-values decrease exponentially as the
score of the match increases. For the search against patented sequences, we used the PATSEQ
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database (113).
C.5 Wet Lab Experiments
C.5.1 MIC Measurement
All of the peptides were amidated at their C-terminus to remove the negative charge of the C-
terminal carboxyl group. Antimicrobial activity of the best AMP hits was evaluated against a
broad spectrum of bacteria for minimum inhibitory concentration (MIC), which include Gram-
positive Staphylococcus aureus (ATCC 29737), Gram-negative Escherichia coli (ATCC 25922),
Pseudomonas aeruginosa (ATCC 9027) and multi-drug resistant K. pneumoniae (ATCC 700603),
which produce beta-lactamase SHV 18. The broth microdilution method was used to measure
MIC values of the AMPs, and the detailed protocol was reported previously (114, 115).
C.5.2 Hemolytic Activity
The selectivity of AMPs towards bacteria over mammalian cells was studied using rat red blood
cells (rRBCs), which were obtained from the Animal Handling Unit of Biomedical Research
Center, Singapore. Negative control: Untreated rRBC suspension in phosphate-buffered saline
(PBS); Positive control: rRBC suspension treated with 0.1% Triton X. Percentage of hemolysis
of rRBCs was obtained using the following formula:
Hemolysis(%) =
O.D.576nm of treated samples −O.D.576nm of negative control
O.D.576nm of positive samples−O.D.576nm of negative control (6)
C.5.3 Acute in Vivo Toxicity Analysis
The animal study protocols were approved by the Institutional Animal Care and Use Commit-
tee of Biological Resource Center, Agency for Science, technology, and Research (A*STAR),
Singapore. LD50 values of the AMPs, the dose required to kill 50% mice, were determined us-
ing a previously reported protocol (116). Specifically, female Balb/c mice (8 weeks old, 18-22
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g) were employed. AMPs were dissolved in saline and administered to mice by intraperitoneal
(i.p.) injection at various doses. Mortality was monitored for 14 days post-AMP administration,
and LD50 was estimated using the maximum likelihood method.
C.5.4 CD Spectroscopy
The peptides were dissolved at 0.5 mg/mL in either deionized water or deionized water con-
taining 25 mM SDS surfactant. It forms anioic micelles in aqueous solution, which mimic the
bacterial membrane. The CD spectra were measured using a CD spectropolarimeter from Jasco
Corp. J-810 at room temperature and a quartz cuvette with 1 mm path length. The spectra were
acquired by scanning from 190 to 260 nm at 10nm/min after subtraction with the spectrum of
the solvent.
E-value <= 0.001 <= 0.01 <= 0.1 <= 1 <= 10 > 10
Labeled 9.36 3.42 9.70 29.59 29.88 18.05
Unlabeled 5.16 4.05 9.07 30.97 36.65 14.08
Table S3: Percentage of CLaSS-generated AMP sequences in different categories of Expect
value (E-value). E-value for the match with the highest score was considered, as obtained by
performing BLAST similarity search against AMP-labeled training sequences (top row) and
unlabeled training sequences (bottom row).
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k Generated AMP AMP-labeled Training Unlabeled Training
3 0.299± 0.006 0.223± 0.006 0.110± 0.005
4 0.771± 0.004 0.607± 0.002 0.777± 0.001
5 0.947± 0.002 0.706± 0.002 0.965± 0.000
6 0.978± 0.001 0.742± 0.002 0.983± 0.001
(a) Fraction of unique k-mer present in different datasets. k = 3-6. The mean
and standard errors were estimated on three different sets, each consisting of
3000 randomly chosen samples.
Kmers
Generated AMP AMP-labeled Training Unlabeled Training
top-3 Frequency top-3 Frequency top-3 Frequency
3
KKK 0.011 KKK 0.006 LLL 0.002
LKK 0.007 KKL 0.004 LAA 0.001
KLK 0.007 GLL 0.004 RRR 0.001
4
KKKK 0.005 KKKK 0.003 PLDL 0.001
KLKK 0.004 KKLL 0.002 LDLA 0.001
KKLK 0.003 KLLK 0.002 NFPL 0.001
(b) Top 3 k-mers (k = 3 and 4) and their corresponding frequency in generated AMPs,
training AMPs, and unlabeled training sequences. The estimated standard deviation
values were close to zero.
Generated AMP AMP-labeled Training Unlabeled Training
Charge 2.695± 0.039 3.074± 0.238 1.172± 0.218
Charge Density 0.002± 0.000 0.002± 0.000 0.001± 0.000
Aliphatic Index 107.814± 0.649 101.232± 1.550 82.088± 8.440
Aromaticity 0.095± 0.002 0.102± 0.002 0.082± 0.003
Hydrophobicity 0.048± 0.007 0.068± 0.002 0.052± 0.032
Hydrophobic Moment 0.331± 0.000 0.335± 0.019 0.222± 0.003
Hydrophobic Ratio 0.446± 0.001 0.431± 0.010 0.425± 0.013
(c) Physicochemical properties, such as charge, charge density, aliphatic index, aromaticity, hy-
drophobicity, hydrophobic moment, hydrophobic ratio, instability index, were estimated on unlabeled
training, AMP-labeled training, and generated AMP sequences using CLaSS. Mean, and standard de-
viation were estimated on three different sets, each consisting of 3000 randomly chosen samples.
Figure S1: Comparison of CLaSS-generated AMPs with AMP-labeled and unlabeled peptides.
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(A) (B) (C)
Sequence Score E-Value % Coverage % Identity % Positive % Gap
YLRLIRYMAKMI 21.88 1.20 66.67 75.00 75.00 75.00
FPLTWLKWWKWKK 33.30 4e-05 84.61 73.00 73.00 9.00
Figure S2: Percentage of hemolysis of rat red blood cells as a function of peptide concen-
tration. (B) and (C) show CD Spectra of YI12 and FK13 peptide, respectively, at 0.5 mg/ml
concentration in DI water and presence of 20 mM SDS buffer. Both YI12 and FK13 showed a
random coil-like structure in the absence of SDS. When SDS was present, both sequences form
α-helical structure (evident from the 208 nm and 222 nm peaks). (D) BLAST search results
(alignment score, E-value, percentage of alignment coverage, percentage of identity, percent-
age of positive matches or similarity, percentage of alignment gap) against full training data for
YI12 and FK13.
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Sequence Positive Residue Binding time (ns) Mean Variance
YLRLIRYMAKMI 3 210 6.45 1.27
FPLTWLKWWKWKK 4 90 5.90 1.39
HILRMRIRQMMT 3 17 7.84 1.44
ILLHAILGVRKKL 3 105 7.16 1.19
YRAAMLRRQYMMT 3 19 8.79 1.25
HIRLMRIRQMMT 3 493 8.38 1.50
HIRAMRIRAQMMT 3 39 7.20 1.39
KTLAQLSAGVKRWH 3 177 7.62 1.46
HILRMRIRQGMMT 3 62 8.37 1.53
HRAIMLRIRQMMT 3 297 7.46 1.35
EYLIEVRESAKMTQ 2 150 6.65 1.79
GLITMLKVGLAKVQ 2 341 8.34 1.58
YQLLRIMRINIA 2 239 6.29 1.71
VRWIEYWREKWRT 4 125 6.41 1.28
LIQVAPLGRLLKRR 4 37 6.52 1.24
YQLRLIMKYAI 2 192 7.75 1.86
HRALMRIRQCMT 3 80 9.15 1.27
GWLPTEKWRKLC 3 227 6.11 1.63
YQLRLMRIMSRI 3 349 8.28 1.80
LRPAFKVSK 3 151 7.73 1.85
Table S4: Physics-derived features such as mean and variance of the number of contacts be-
tween positive amino acids and membrane beads (that are found to be associated with antimi-
crobial function in this study), as extracted from CGMD simulations of peptide membrane
interactions for the top 20 AI-designed AMP sequences.
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Sequence Length Charge H µH
YLRLIRYMAKMI 12 3.99 0.08 0.79
FPLTWLKWWKWKK 13 5.00 0.05 0.20
HILRMRIRQMMT 12 4.10 -0.25 0.36
ILLHAILGVRKKL 13 4.09 0.27 0.33
YRAAMLRRQYMMT 13 3.99 -0.28 0.06
HIRLMRIRQMMT 12 4.10 -0.25 0.16
HIRAMRIRAQMMT 13 4.10 -0.22 0.24
KTLAQLSAGVKRWH 14 4.09 -0.08 0.49
HILRMRIRQGMMT 13 4.10 -0.19 0.27
HRAIMLRIRQMMT 13 4.10 -0.18 0.41
EYLIEVRESAKMTQ 14 0.00 -0.16 0.26
GLITMLKVGLAKVQ 14 3.00 0.37 0.28
YQLLRIMRINIA 12 3.00 0.11 0.38
VRWIEYWREKWRT 13 3.00 -0.41 0.55
LIQVAPLGRLLKRR 14 5.00 -0.12 0.38
YQLRLIMKYAI 11 2.99 0.18 0.40
HRALMRIRQCMT 12 4.03 -0.34 0.56
GWLPTEKWRKLC 12 2.93 -0.13 0.33
YQLRLMRIMSRI 12 4.00 -0.17 0.64
LRPAFKVSK 9 4.00 -0.17 0.70
Table S5: Physico-chemical properties for the top 20 AI-designed AMP sequences.
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Sequence S. aureus (µg/mL) E.Coli (µg/mL)
YLRLIRYMAKMI-CONH2 7.8 31.25
FPLTWLKWWKWKK-CONH2 15.6 31.25
HILRMRIRQMMT-CONH2 >1000 >1000
ILLHAILGVRKKL-CONH2 250 250
YRAAMLRRQYMMT-CONH2 >1000 >1000
HIRLMRIRQMMT-CONH2 >1000 >1000
HIRAMRIRAQMMT-CONH2 >1000 1000
KTLAQLSAGVKRWH-CONH2 >1000 >1000
HILRMRIRQGMMT-CONH2 >1000 >1000
HRAIMLRIRQMMT-CONH2 >1000 >1000
EYLIEVRESAKMTQ-CONH2 >1000 >1000
GLITMLKVGLAKVQ-CONH2 >1000 >1000
YQLLRIMRINIA-CONH2 >1000 >1000
VRWIEYWREKWRT-CONH2 >1000 >1000
YQLRLIMKYAI-CONH2 125 125
HRALMRIRQCMT-CONH2 1000 1000
GWLPTEKWRKLC-CONH2 1000 >1000
YQLRLMRIMSRI-CONH2 250 500
FFPLPAISTELKRL-CONH2 >1000 >1000
LIQVAPLGRLLKRR-CONH2 >1000 1000
LRPAFKVSK-CONH2 >1000 >1000
Table S6: Broad-spectrum MIC values of top 20 AI-designed AMP Sequences
Sequence S. aureus (µg/mL) E.Coli (µg/mL)
AMLELARIIGRR-CONH2 >1000 >1000
IPRPGPFVDPRSR-CONH2 >1000 >1000
VAKVFRAPKVPICP-CONH2 >1000 >1000
FPSFTFRLRKWKRG-CONH2 62.5 62.5
RPPFGPPFRR-CONH2 >1000 >1000
WEEMDSLRKWRIWS-CONH2 >1000 >1000
RRQAQEVRGPRH-CONH2 >1000 >1000
KKKKPLTPDFVFF-CONH2 >1000 >1000
TRGPPPTFRAFR-CONH2 >1000 >1000
LALHLEALIAGRR-CONH2 250 >1000
Table S7: Broad-spectrum MIC values of 11 AI-designed Non-AMP Sequences
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